Cardiolyse Company Profile

Background

Mission and Vision

Cardiolyse is dedicated to enhancing longevity and preventing heart disorders among high-risk groups through innovative, clinically validated predictive algorithms. The company's vision is to integrate seamlessly into global health monitoring systems, offering superior prognostic tools for managing heart health and leading the prediction of cardiovascular diseases (CVD), chronic fatigue, and burnout.

Industry Significance

Operating within the digital healthcare sector, Cardiolyse focuses on the analytics of human heart electro signals, providing cardiocare anytime, anywhere. Its cloud-based ECG and HRV analytics platform enables real-time remote heart health monitoring, delivering personalized reports and data-driven prognoses for dangerous heart events.

Key Strategic Focus

Core Objectives and Specialization

Cardiolyse specializes in cloud-based ECG and HRV analytics, aiming to prevent heart disorders in high-risk groups through innovative, clinically proven machine-learning algorithms. The platform integrates with various digital ECG devices, monitors and analyzes ECG recordings, and detects all types of arrhythmias, atrial fibrillation, myocardial infarction, and ventricular hypertrophy.

Key Technologies and Target Markets

The company's proprietary technologies include patent-pending Universal ECG and Personal Baseline Scores, which predict heart attacks and strokes up to two months in advance. Cardiolyse targets healthcare providers, telemedicine platforms, device manufacturers, insurance companies, and pharmaceutical companies, offering solutions for remote real-time heart health monitoring, diabetes cardiovascular comorbidities prevention, and fatigue risk management.

Financials and Funding

Funding History

Cardiolyse has successfully raised over €600,000 for its initial platform development, market research, and clinical trials. Notable funding rounds include a seed round in July 2018, raising $17,500 led by Startupbootcamp Digital Health Berlin, and a non-equity assistance round in August 2022 led by Google for Startups.

Utilization of Capital

The capital raised has been allocated towards platform development, market research, clinical trials, and pilot projects with key players in the insurance and pharmaceutical sectors, as well as hospital inpatient and outpatient units.

Pipeline Development

Key Pipeline Candidates and Development Stages

Cardiolyse's platform is designed for real-time remote heart health monitoring, providing personalized reports and up to two months' data-based prognosis on dangerous heart events. The company has conducted pilot projects, including a fatigue risk management proof of concept for liability insurance and a cardiac screening for rural area citizens in Ukraine.

Target Conditions and Milestones

The platform targets conditions such as arrhythmias, atrial fibrillation, myocardial infarction, and ventricular hypertrophy. Significant milestones include the CE certification of its algorithms and ongoing research collaborations with institutions like Oxford University.

Technological Platform and Innovation

Proprietary Technologies

Cardiolyse's platform features patent-pending Universal ECG and Personal Baseline Scores, enabling precise prediction of heart attacks and strokes up to two months before occurrence. The device-agnostic solution integrates with any digital ECG device, processing and analyzing ECG recordings of any lead number.

Scientific Methodologies

The platform employs clinically proven machine-learning algorithms that analyze up to 400 vital ECG parameters, detecting all types of arrhythmias, atrial fibrillation, myocardial infarction, and ventricular hypertrophy. These algorithms are CE-certified and form the core of Cardiolyse's ECG processing capabilities.

Leadership Team

Executive Profiles

Anna Starynska, Chief Executive Officer: With a Master’s in Computer & Data Science and over 25 years of experience in leading multinational projects, including European Commission initiatives and Global Tuberculosis Fund projects. Anna is a serial entrepreneur who bootstrapped Cardiolyse with her life savings.

Illya Chaikovsky, Chief Science Officer: An MD with multiple PhDs and over 30 years of practice in cardiology. Illya is a globally renowned scientist whose experience forms the core of Cardiolyse's CE-certified ECG processing algorithms and patents.

Normunds Daudiss, Chief Executive Officer: An experienced healthcare leader with over 15 years in B2B projects and innovation commercialization.

Irina Zharuk, Chief Operating Officer: With over 15 years of experience in public health project management.

Max Boreiko, AI Advisor: Holds an MSc in medical physics with over six years of experience in medical algorithms.

Advisory Board

Cosimo Pulli, Global Development Advisor: An executive with over 25 years of experience in business development.

Pekka Pirttiaho, Global Development Advisor: A MedTech solutions growth expert with over 15 years in sales for large and small ventures.

Massimo Gualerzi, Scientific Advisor: An experienced medical director and cardiologist, leading non-profits and corporate scientific divisions.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within Cardiolyse's leadership team.

Competitor Profile

Market Insights and Dynamics

The digital healthcare market, particularly in remote heart health monitoring, is experiencing significant growth due to increasing prevalence of cardiovascular diseases and advancements in wearable technology. The demand for predictive analytics and personalized health monitoring solutions is driving innovation and competition in this sector.

Competitor Analysis

Key competitors in the remote heart health monitoring space include:

Vantage Fit: A corporate wellness software designed to promote employee health and well-being through personalized wellness programs.

YuLife: A platform combining wellness challenges, reward-based systems, and personalized wellness journeys to create a healthier workforce.

Optimity: Offers wellness activities, including fitness challenges, mindfulness sessions, and nutrition guides, to promote healthier lifestyles among employees.

Sprout: Provides a platform for creating, managing, and tracking wellness programs, ensuring businesses can effectively promote a healthy and engaged workforce.

These competitors focus on corporate wellness and employee engagement, offering features that overlap with Cardiolyse's remote heart health monitoring capabilities.

Strategic Collaborations and Partnerships

Cardiolyse has engaged in significant collaborations to strengthen its market position and innovation capacity:

Oxford University: Ongoing research on analyzing 500,000 ECG recordings.

Startup Creasphere by Plug and Play: Participated in a 3-month accelerator program, showcasing pilot outcomes at the Munich Summer Summit.

Health&BioTech Accelerator by Deloitte Italy: Selected among six international startups to participate in the program coordinated by Deloitte Officine Innovazione.

Operational Insights

Cardiolyse's strategic considerations include:

Market Position: Positioning itself as a leader in predictive cardiac analytics through innovative, clinically validated algorithms.

Competitive Advantages: Offering a device-agnostic, cloud-based platform with CE-certified algorithms capable of predicting heart events up to two months in advance.